Impact BioMedical, INC. Goodwill, Period Increase (Decrease)
Impact BioMedical, INC. (IBO) reported Goodwill, Period Increase (Decrease) of -$25.09 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Notes › Goodwill and Other
us-gaap:GoodwillPeriodIncreaseDecrease · last filed 2025-11-07
- Impact BioMedical, INC. goodwill, period increase (decrease) for the quarter ending 2025-09-30 was $0.00.
- Impact BioMedical, INC. goodwill, period increase (decrease) for the quarter ending 2025-06-30 was $0.00.
- Impact BioMedical, INC. goodwill, period increase (decrease) for the quarter ending 2025-03-31 was -$25.09M.
- Impact BioMedical, INC. goodwill, period increase (decrease) for fiscal 2024 was -$25.09M.
| Period end | Goodwill, Period Increase (Decrease) 3 month | Goodwill, Period Increase (Decrease) 6 month | Goodwill, Period Increase (Decrease) 9 month | Goodwill, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | -$25.09M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$25.09M 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | -$25.09M 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | -$25.09M 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |